Cost-Utility Analysis of Gastric Bypass for Severely Obese Patients in Spain

被引:16
|
作者
Castilla, Ivan [1 ,2 ,4 ]
Mar, Javier [1 ,3 ]
Valcarcel-Nazco, Cristina [2 ,4 ]
Arrospide, Arantzazu [1 ,3 ]
Ramos-Goni, Juan M. [1 ,5 ]
机构
[1] Hlth Serv Res Chron Patients Network REDISSEC, Santa Cruz De Tenerife, Spain
[2] Univ La Laguna, Ctr Biomed Res Canary Isl, E-38207 San Cristobal la Laguna, Spain
[3] Alto Deba Hosp, Clin Management Serv, Arrasate Mondragon, Spain
[4] Canary Isl Fdn Hlth & Res FUNCIS, Santa Cruz De Tenerife, Spain
[5] Canary Isl Hlth Serv SESCS, HTA Unit, Santa Cruz De Tenerife, Spain
关键词
Cost-utility; Discrete-event simulation; Gastric bypass; QUALITY-OF-LIFE; BARIATRIC SURGERY; RISK; MORTALITY; COMORBIDITIES; SURVIVAL; WEIGHT; STROKE; TRENDS; IMPACT;
D O I
10.1007/s11695-014-1304-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background To assess the cost-utility of gastric bypass versus usual care for patients with severe obesity in Spain. Methods We have implemented a discrete-event simulation model with two branches: one branch involves gastric bypass, thereby reducing patients' BMI, and another branch where patients do not undergo surgery. The model analyzes the emergence of comorbidities (stroke, coronary obstructive disease, diabetes, and breast cancer) associated with obesity during a lifetime horizon. The selected measure of effectiveness is health-related quality of life. Both costs and effects are discounted at 3 %. A probabilistic sensitivity analysis is also performed using second-order Monte Carlo simulation; acceptability curves for different time horizons were also calculated. Results Patients with gastric bypass result in a lifetime increase of 5.63 quality-adjusted life years (QALYs) (18.18 vs. 12.55 QALYs). In addition, because of the reduced spending associated with the treatment of various obesity-related comorbidities, final savings stand at 13,994 (sic). The total cost of the intervention branch is close to half the cost of the nonintervention branch (17,431 vs. 31,425 (sic)). Conclusions Gastric bypass is an intervention that dominates over the option of not intervening when a lifetime horizon is considered.
引用
收藏
页码:2061 / 2068
页数:8
相关论文
共 50 条
  • [21] Cost-utility analysis - Response
    Neumann, PJ
    Chapman, RH
    Stone, PW
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 626 - 626
  • [22] Cost-utility analysis and otolaryngology
    Hamilton, D.
    Hulme, C.
    Flood, L.
    Powell, S.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2014, 128 (02): : 112 - 118
  • [23] Cost-utility analysis of evolocumab in patients with ASCVD in Italy
    Marcellusi, Andrea
    Bini, Chiara
    Rotundo, Maria Assunta
    Arcangeli, Emanuela
    Martinez, Laura
    Vilela, Francesc Sorio
    Mennini, Francesco Saverio
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 155 - 167
  • [24] Cost-utility analysis of the rehabilitation of patients with musculoskeletal problems
    Jonsson D.
    Husberg M.
    Götherström U.
    International Advances in Economic Research, 2000, 6 (4) : 741 - 748
  • [25] Health Outcomes of Gastric Bypass Patients Compared to Nonsurgical, Nonintervened Severely Obese
    Adams, Ted D.
    Pendleton, Robert C.
    Strong, Michael B.
    Kolotkin, Ronette L.
    Walker, James M.
    Litwin, Sheldon E.
    Berjaoui, Wael K.
    LaMonte, Michael J.
    Cloward, Tom V.
    Avelar, Erick
    Owan, Theophilus E.
    Nuttall, Robert T.
    Gress, Richard E.
    Crosby, Ross D.
    Hopkins, Paul N.
    Brinton, Eliot A.
    Rosamond, Wayne D.
    Wiebke, Gail A.
    Yanowitz, Frank G.
    Farney, Robert J.
    Halverson, R. Chad
    Simper, Steven C.
    Smith, Sherman C.
    Hunt, Steven C.
    OBESITY, 2010, 18 (01) : 121 - 130
  • [26] Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain
    Álvaro Hidalgo-Vega
    Juan Manuel Ramos-Goñi
    Renata Villoro
    The European Journal of Health Economics, 2014, 15 : 917 - 925
  • [27] COST-UTILITY OF RHEUMATOID ARTHRITIS MONOTHERAPY WITH TOCILIZUMAB IN SPAIN
    Benito Ruiz, P.
    Navarro Sarabia, F.
    Gomez Reino, J.
    Poveda, J.
    Alvaro Gracia, J.
    Rubio-Rodriguez, D.
    Ruiz-Beato, E.
    VALUE IN HEALTH, 2013, 16 (07) : A565 - A565
  • [28] COST-UTILITY OF DENOSUMAB FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SPAIN
    Darba, J.
    Kaskens, L.
    Sorio, F.
    VALUE IN HEALTH, 2011, 14 (07) : A311 - A311
  • [29] Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain
    Hidalgo-Vega, Alvaro
    Manuel Ramos-Goni, Juan
    Villoro, Renata
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (09): : 917 - 925
  • [30] Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
    Darba, Josep
    Kaskens, Lisette
    Vilela, Francesc Sorio
    Lothgren, Mickael
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 105 - 117